The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer

Science Advances

Volumn 2, Issue 10, 2016, Pages

  Law, Emily K ^a,b,c   Sieuwerts, Anieta M ^d   Lapara, Kelly ^b   Leonard, Brandon ^a,b,c   Starrett, Gabriel J ^a,b,c   Molan, Amy M ^a,b,c   Temiz, Nuri A ^a,b,c   Vogel, Rachel Isaksson ^a,b   Meijer Van Gelder, Marion E ^d   Sweep, Fred C G J ^e   Span, Paul N ^e   Foekens, John A ^d   Martens, John W M ^d   Yee, Douglas ^b   Harris, Reuben S ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; CATALYST ACTIVITY; CELL CULTURE; DISEASES; DNA; DRUG THERAPY; ENZYME ACTIVITY; ENZYMES; TUMORS;

APOLIPOPROTEIN B; BREAST CANCER CELLS; CHROMOSOMAL ABERRATION; ESTROGEN RECEPTOR; GENETIC HETEROGENEITIES; OVER-EXPRESSION; SOMATIC MUTATION; THERAPEUTIC EFFICACY;

ELECTRIC RESISTANCE;

APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; TAMOXIFEN;

ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENE DELETION; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CYTIDINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; HETEROGRAFTS; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM TRANSPLANTATION; TAMOXIFEN;

EID: 85011350603     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1601737     Document Type: Article

References (55)

1. E. B. Elkin, C. A. Hudis, Parsing progress in breast cancer. J. Clin. Oncol. 33, 2837-2838 (2015).
2. J. H. Park, W. F. Anderson, M. H. Gail, Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J. Clin. Oncol. 33, 2870-2876 (2015).
3. T. Saphner, D. C. Tormey, R. Gray, Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738-2746 (1996).
4. H. J. Burstein, S. Temin, H. Anderson, T. A. Buchholz, N. E. Davidson, K. E. Gelmon, S. H. Giordano, C. A. Hudis, D. Rowden, A. J. Solky, V. Stearns, E. P. Winer, J. J. Griggs, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol. 32, 2255-2269 (2014).
5. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, V. Raina, M. Abraham, V. H. Medeiros Alencar, A. Badran, X. Bonfill, J. Bradbury, M. Clarke, R. Collins, S. R. Davis, A. Delmestri, J. F. Forbes, P. Haddad, M.-F. Hou, M. Inbar, H. Khaled, J. Kielanowska, W. H. Kwan, B. S. Mathew, I. Mittra, B. Müller, A. Nicolucci, O. Peralta, F. Pernas, L. Petruzelka, T. Pienkowski, R. Radhika, B. Rajan, M. T. Rubach, S. Tort, G. Urrútia, M. Valentini, Y. Wang, R. Peto; Adjuvant Tamoxifen: Longer Against Shorter Collaborative, Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805-816 (2013).
6. S. Nik-Zainal, L. B. Alexandrov, D. C. Wedge, P. Van Loo, C. D. Greenman, K. Raine, D. Jones, J. Hinton, J. Marshall, L. A. Stebbings, A. Menzies, S. Martin, K. Leung, L. Chen, C. Leroy, M. Ramakrishna, R. Rance, K. W. Lau, L. J. Mudie, I. Varela, D. J. McBride, G. R. Bignell, S. L. Cooke, A. Shlien, J. Gamble, I. Whitmore, M. Maddison, P. S. Tarpey, H. R. Davies, E. Papaemmanuil, P. J. Stephens, S. McLaren, A. P. Butler, J. W. Teague, G. Jönsson, J. E. Garber, D. Silver, P. Miron, A. Fatima, S. Boyault, A. Langerød, A. Tutt, J. W. M. Martens, S. A. J. R. Aparicio, Å. Borg, A. V. Salomon, G. Thomas, A.-L. Børresen-Dale, A. L. Richardson, M. S. Neuberger, P. A. Futreal, P. J. Campbell, M. R. Stratton; Breast Cancer Working Group of the International Cancer Genome Consortium, Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
7. M. B. Burns, L. Lackey, M. A. Carpenter, A. Rathore, A. M. Land, B. Leonard, E. W. Refsland, D. Kotandeniya, N. Tretyakova, J. B. Nikas, D. Yee, N. A. Temiz, D. E. Donohue, R. M. McDougle, W. L. Brown, E. K. Law, R. S. Harris, APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
8. M. B. Burns, N. A. Temiz, R. S. Harris, Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977-983 (2013).
9. S. A. Roberts, M. S. Lawrence, L. J. Klimczak, S. A. Grimm, D. Fargo, P. Stojanov, A. Kiezun, G. V. Kryukov, S. L. Carter, G. Saksena, S. Harris, R. R. Shah, M. A. Resnick, G. Getz, D. A. Gordenin, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013).
10. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin, G. R. Bignell, N. Bolli, A. Borg, A.-L. Børresen-Dale, S. Boyault, B. Burkhardt, A. P. Butler, C. Caldas, H. R. Davies, C. Desmedt, R. Eils, J. E. Eyfjörd, J. A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinsk, N. Jäger, D. T. W. Jones, D. Jones, S. Knappskog, M. Kool, S. R. Lakhani, C. López-Otín, S. Martin, N. C. Munshi, H. Nakamura, P. A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X. S. Puente, K. Raine, M. Ramakrishna, A. L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. N. Schumacher, P. N. Span, J. W. Teague, Y. Totoki, A. N. J. Tutt, R. Valdés-Mas, M. M. van Buuren, L. van't Veer, A. Vincent-Salomon, N. Waddell, L. R. Yates; J. Zucman-Rossi, P. A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. M. Grimmond, R. Siebert, E. Campo, T. Shibata, S. M. Pfister, P. J. Campbell, M. R. Stratton, Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
11. C. Swanton, N. McGranahan, G. J. Starrett, R. S. Harris, APOBEC enzymes: Mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704-712 (2015).
12. S. A. Roberts, D. A. Gordenin, Hypermutation in human cancer genomes: Footprints and mechanisms. Nat. Rev. Cancer 14, 786-800 (2014).
13. T. Helleday, S. Eshtad, S. Nik-Zainal, Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585-598 (2014).
14. M. H. Malim, P. D. Bieniasz, HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2, a006940 (2012).
15. S. Stavrou, S. R. Ross, APOBEC3 proteins in viral immunity. J. Immunol. 195, 4565-4570 (2015).
16. V. Simon, N. Bloch, N. R. Landau, Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546-553 (2015).
17. S. Landry, I. Narvaiza, D. C. Linfesty, M. D. Weitzman, APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12, 444-450 (2011).
18. M. Shinohara, K. Io, K. Shindo, M. Matsui, T. Sakamoto, K. Tada, M. Kobayashi, N. Kadowaki, A. Takaori-Kondo, APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep. 2, 806 (2012).
19. B. J. M. Taylor, S. Nik-Zainal, Y. L. Wu, L. A. Stebbings, K. Raine, P. J. Campbell, C. Rada, M. R. Stratton, M. S. Neuberger, DNA deaminases induce break-Associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. ELife 2, e00534 (2013).
20. B. Mussil, R. Suspène, M.-M. Aynaud, A. Gauvrit, J.-P. Vartanian, S. Wain-Hobson, Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLOS One 8, e73641 (2013).
21. V. Caval, R. Suspène, M. Shapira, J.-P. Vartanian, S. Wain-Hobson, A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat. Commun. 5, 5129 (2014).
22. B. Leonard, J. L. McCann, G. J. Starrett, L. Kosyakovsky, E. M. Luengas, A. M. Molan, M. B. Burns, R. M. McDougle, P. J. Parker, W. L. Brown, R. S. Harris, The PKC/NF-kB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 75, 4538-4547 (2015).
23. A. M. Sieuwerts, S. Willis, M. B. Burns, M. P. Look, M. E. Meijer-Van Gelder, A. Schlicker, M. R. Heideman, H. Jacobs, L. Wessels, B. Leyland-Jones, K. P. Gray, J. A. Foekens, R. S. Harris, J. W. M. Martens, Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 5, 405-413 (2014).
24. D. W. Cescon, B. Haibe-Kains, T. W. Mak, APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. U.S.A. 112, 2841-2846 (2015).
25. L. R. Yates, M. Gerstung, S. Knappskog, C. Desmedt, G. Gundem, P. Van Loo, T. Aas, L. B. Alexandrov, D. Larsimont, H. Davies, Y. Li, Y. S. Ju, M. Ramakrishna, H. K. Haugland, P. K. Lilleng, S. Nik-Zainal, S. McLaren, A. Butler, S. Martin, D. Glodzik, A. Menzies, K. Raine, J. Hinton, D. Jones, L. J. Mudie, B. Jiang, D. Vincent, A. Greene-Colozzi, P.-Y. Adnet, A. Fatima, M. Maetens, M. Ignatiadis, M. R. Stratton, C. Sotiriou, A. L. Richardson, P. E. Lønning, D. C. Wedge, P. J. Campbell, Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
26. A. N. Hata, M. J. Niederst, H. L. Archibald, M. Gomez-Caraballo, F. M. Siddiqui, H. E. Mulvey, Y. E. Maruvka, F. Ji, H. E. Bhang, V. Krishnamurthy Radhakrishna, G. Siravegna, H. Hu, S. Raoof, E. Lockerman, A. Kalsy, D. Lee, C. L. Keating, D. A. Ruddy, L. J. Damon, A. S. Crystal, C. Costa, Z. Piotrowska, A. Bardelli, A. J. Iafrate, R. I. Sadreyev, F. Stegmeier, G. Getz, L. V. Sequist, A. C. Faber, J. A. Engelman, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262-269 (2016).
27. K. Kemper, O. Krijgsman, P. Cornelissen-Steijger, A. Shahrabi, F. Weeber, J.-Y. Song, T. Kuilman, D. J. Vis, L. F. Wessels, E. E. Voest, T. N. M. Schumacher, C. U. Blank, D. J. Adams, J. B. Haanen, D. S. Peeper, Intra-And inter-Tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104-1118 (2015).
28. S. Nik-Zainal, H. Davies, J. Staaf, M. Ramakrishna, D. Glodzik, X. Zou, I. Martincorena, L. B. Alexandrov, S. Martin, D. C. Wedge, P. Van Loo, Y. S. Ju, M. Smid, A. B. Brinkman, S. Morganella, M. R. Aure, O. C. Lingjærde, A. Langerød, M. Ringnér, S.-M. Ahn, S. Boyault, J. E. Brock, A. Broeks, A. Butler, C. Desmedt, L. Dirix, S. Dronov, A. Fatima, J. A. Foekens, M. Gerstung, G. K. J. Hooijer, S. J. Jang, D. R. Jones, H.-Y. Kim, T. A. King, S. Krishnamurthy, H.-J. Lee, J. Y. Lee, Y. Li, S. McLaren, A. Menzies, V. Mustonen, S. O'Meara, I. Pauporté, X. Pivot, C. A. Purdie, K. Raine, K. Ramakrishnan, F. G. Rodríguez-González, G. Romieu, A. M. Sieuwerts, P. T. Simpson, R. Shepherd, L. Stebbings, O. A. Stefansson, J. Teague, S. Tommasi, I. Treilleux, G. G. Van den Eynden, P. Vermeulen, A. Vincent-Salomon, L. Yates, C. Caldas, L. van't Veer, A. Tutt, S. Knappskog, B. K. T. Tan, J. Jonkers, Å. Borg, N. T. Ueno, C. Sotiriou, A. Viari, P. A. Futreal, P. J. Campbell, P. N. Span, S. Van Laere, S. R. Lakhani, J. E. Eyfjord, A. M. Thompson, E. Birney, H. G. Stunnenberg, M. J. van de Vijver, J. W. M. Martens, A.-L. Børresen-Dale, A. L. Richardson, G. Kong, G. Thomas, M. R. Stratton, Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
29. D. Juric, P. Castel, M. Griffith, O. L. Griffith, H. H. Won, H. Ellis, S. H. Ebbesen, B. J. Ainscough, A. Ramu, G. Iyer, R. H. Shah, T. Huynh, M. Mino-Kenudson, D. Sgroi, S. Isakoff, A. Thabet, L. Elamine, D. B. Solit, S. W. Lowe, C. Quadt, M. Peters, A. Derti, R. Schegel, A. Huang, E. R. Mardis, M. F. Berger, J. Baselga, M. Scaltriti, Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature 518, 240-244 (2015).
30. S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, A. Bashashati, L. M. Prentice, J. Khattra, A. Burleigh, D. Yap, V. Bernard, A. McPherson, K. Shumansky, A. Crisan, R. Giuliany, A. Heravi-Moussavi, J. Rosner, D. Lai, I. Birol, R. Varhol, A. Tam, N. Dhalla, T. Zeng, K. Ma, S. K. Chan, M. Griffith, A. Moradian, S.-W. G. Cheng, G. B. Morin, P. Watson, K. Gelmon, S. Chia, S.-F. Chin, C. Curtis, O. M. Rueda, P. D. Pharoah, S. Damaraju, J. Mackey, K. Hoon, T. Harkins, V. Tadigotla, M. Sigaroudinia, P. Gascard, T. Tlsty, J. F. Costello, I. M. Meyer, C. J. Eaves, W. W. Wasserman, S. Jones, D. Huntsman, M. Hirst, C. Caldas, M. A. Marra, S. Aparicio, The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
31. S. Nik-Zainal, P. Van Loo, D. C. Wedge, L. B. Alexandrov, C. D. Greenman, K. W. Lau, K. Raine, D. Jones, J. Marshall, M. Ramakrishna, A. Shlien, S. L. Cooke, J. Hinton, A. Menzies, L. A. Stebbings, C. Leroy, M. Jia, R. Rance, L. J. Mudie, S. J. Gamble, P. J. Stephens, S. McLaren, P. S. Tarpey, E. Papaemmanuil, H. R. Davies, I. Varela, D. J. McBride, G. R. Bignell, K. Leung, A. P. Butler, J. W. Teague, S. Martin, G. Jönsson, O. Mariani, S. Boyault, P. Miron, A. Fatima, A. Langerød, S. A. J. R. Aparicio, A. Tutt, A. M. Sieuwerts, Å. Borg, G. Thomas, A. V. Salomon, A. L. Richardson, A.-L. Børresen-Dale, P. A. Futreal, M. R. Stratton, P. J. Campbell, The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
32. E. C. de Bruin, N. McGranahan, R. Mitter, M. Salm, D. C. Wedge, L. Yates, M. Jamal-Hanjani, S. Shafi, N. Murugaesu, A. J. Rowan, E. Grönroos, M. A. Muhammad, S. Horswell, M. Gerlinger, I. Varela, D. Jones, J. Marshall, T. Voet, P. Van Loo, D. M. Rassl, R. C. Rintoul, S. M. Janes, S.-M. Lee, M. Forster, T. Ahmad, D. Lawrence, M. Falzon, A. Capitanio, T. T. Harkins, C. C. Lee, W. Tom, E. Teefe, S.-C. Chen, S. Begum, A. Rabinowitz, B. Phillimore, B. Spencer-Dene, G. Stamp, Z. Szallasi, N. Matthews, A. Stewart, P. Campbell, C. Swanton, Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
33. A. M. Sieuwerts, M. B. Lyng, M. E. Meijer-van Gelder, V. de Weerd, F. C. Sweep, J. A. Foekens, P. N. Span, J. W. Martens, H. J. Ditzel, Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. Mol. Oncol. 8, 1679-1689 (2014).
34. A. V. Lee, S. Oesterreich, N. E. Davidson, MCF-7 cells-Changing the course of breast cancer research and care for 45 years. J. Natl. Cancer Inst. 107, djv073 (2015).
35. Y. H. Ibrahim, S. A. Byron, X. Cui, A. V. Lee, D. Yee, Progesterone receptor-B regulation of insulin-like growth factor-Stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol. Cancer Res. 6, 1491-1498 (2008).
36. D. Sachdev, X. Zhang, I. Matise, M. Gaillard-Kelly, D. Yee, The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29, 251-262 (2010).
37. J. M. Kidd, T. L. Newman, E. Tuzun, R. Kaul, E. E. Eichler, Population stratification of a common APOBEC gene deletion polymorphism. PLOS Genet. 3, e63 (2007).
38. M. Periyasamy, H. Patel, C.-F. Lai, V. T. M. Nguyen, E. Nevedomskaya, A. Harrod, R. Russell, J. Remenyi, A. M. Ochocka, R. S. Thomas, F. Fuller-Pace, B. Gyorffy, C. Caldas, N. Navaratnam, J. S. Carroll, W. Zwart, R. C. Coombes, L. Magnani, L. Buluwela, S. Ali, APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep. 13, 108-121 (2015).
39. K. N. Bishop, R. K. Holmes, A. M. Sheehy, N. O. Davidson, S.-J. Cho, M. H. Malim, Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396 (2004).
40. Q. Yu, D. Chen, R. König, R. Mariani, D. Unutmaz, N. R. Landau, APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279, 53379-53386 (2004).
41. B. P. Doehle, A. Schäfer, B. R. Cullen, Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288 (2005).
42. J. F. Hultquist, J. A. Lengyel, E. W. Refsland, R. S. La Rue, L. Lackey, W. L. Brown, R. S. Harris, Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220-11234 (2011).
43. R. Clarke, J. J. Tyson, J. M. Dixon, Endocrine resistance in breast cancer-An overview and update. Mol. Cell. Endocrinol. 418, 220-234 (2015).
44. R. Jeselsohn, G. Buchwalter, C. De Angelis, M. Brown, R. Schiff, ESR1 mutations-A mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573-583 (2015).
45. K. Shi, M. A. Carpenter, K. Kurahashi, R. S. Harris, H. Aihara, Crystal structure of the DNA deaminase APOBEC3B catalytic domain. J. Biol. Chem. 290, 28120-28130 (2015).
46. H. E. Krokan, F. Drabløs, G. Slupphaug, Uracil in DNA-Occurrence, consequences and repair. Oncogene 21, 8935-8948 (2002).
47. J. M. Di Noia, M. S. Neuberger, Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
48. S. Henderson, A. Chakravarthy, X. Su, C. Boshoff, T. R. Fenton, APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833-1841 (2014).
49. N. McGranahan, C. Swanton, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15-26 (2015).
50. B. Leonard, S. N. Hart, M. B. Burns, M. A. Carpenter, N. A. Temiz, A. Rathore, R. I. Vogel, J. B. Nikas, E. K. Law, W. L. Brown, Y. Li, Y. Zhang, M. J. Maurer, A. L. Oberg, J. M. Cunningham, V. Shridhar, D. A. Bell, C. April, D. Bentley, M. Bibikova, R. K. Cheetham, J.-B. Fan, R. Grocock, S. Humphray, Z. Kingsbury, J. Peden, J. Chien, E. M. Swisher, L. C. Hartmann, K. R. Kalli, E. L. Goode, H. Sicotte, S. H. Kaufmann, R. S. Harris, APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73, 7222-7231 (2013).
51. E. W. Refsland, M. D. Stenglein, K. Shindo, J. S. Albin, W. L. Brown, R. S. Harris, Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274-4284 (2010).
52. M. D. Stenglein, M. B. Burns, M. Li, J. Lengyel, R. S. Harris, APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222-229 (2010).
53. C. S. Ross-Innes, R. Stark, A. E. Teschendorff, K. A. Holmes, H. R. Ali, M. J. Dunning, G. D. Brown, O. Gojis, I. O. Ellis, A. R. Green, S. Ali, S.-F. Chin, C. Palmieri, C. Caldas, J. S. Carroll, Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).
54. L. Lackey, E. K. Law, W. L. Brown, R. S. Harris, Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12, 762-772 (2013).
55. D. C. Koboldt, Q. Zhang, D. E. Larson, D. Shen, M. D. McLellan, L. Lin, C. A. Miller, E. R. Mardis, L. Ding, R. K. Wilson, VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).